Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline (Q34603644)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline |
scientific article |
Statements
1 reference
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline (English)
1 reference
Sagar Lonial
1 reference
Kenneth C Anderson
1 reference
Pieter Sonneveld
1 reference
Thierry Facon
1 reference
Paul G Richardson
1 reference
Hartmut Goldschmidt
1 reference
Edward A Stadtmauer
1 reference
Donna Reece
1 reference
Jesus San Miguel
1 reference
Dixie-Lee Esseltine
1 reference
Jean-Luc Harousseau
1 reference
Jamie D Cavenagh
1 reference
Joan Bladé
1 reference
Mario Boccadoro
1 reference
Patrick Y Wen
1 reference
Michael W Schuster
1 reference
Dina Ben-Yehuda
1 reference
Anthony L Boral
1 reference
Anthony A Amato
1 reference
16 January 2009
1 reference
1 reference
144
1 reference
6
1 reference
895-903
1 reference
Identifiers
1 reference
1 reference